Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pilot open-label randomized trial, frozen FMT by nasogastric tube appeared to be as effective as colonoscopic administration in resolving CDIassociated diarrhea. 126”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [126]
In the citing paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [67]
In the citing paper
“FMT has been examined in both young and old, patients with limited comorbidities as well as those considered to be immunocompromised,43 and the procedure has been shown to be safe, well-tolerated, and effective.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“These include complications of endoscopy, such as perforation and bleeding, and side effects related to sedation, such as aspiration43.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839 · cited 1×
“DNA was extracted and the V4 region of the 16S gene was sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].”
MethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569 · cited 1×
“0 [26] approved by the FDA and institutional review board (IRB).”
BackgroundFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 1×
“In the United States the incidence of CDI has tripled over the last 15 years [3].”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Failure to reconstitute normal flora was shown to be a factor in severe, recurrent, and prolonged illness [13].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 1×
“5 guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, at least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.”
BackgroundSelf-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“The work of Hamilton and Khoruts [28] was used as a guide for fecal manipulation, with the exception that all processes were carried out under ambient air, not nitrogen.”
Method
Research works printed but not linked: 1
- 2013, Clostridium difficile infection in children, JAMA Pediatr, 167, 567, 10.1001/jamapediatrics.2013.441 · DOI · Paper page
Cited by
Items 201–300 of 500
Dehlholm-Lambertsen, E., Hall, B. K., Baunwall, S. M. D., Jørgensen, C. W., Jensen, M. E., Larsen, S., Jensen, J. S., Ehlers, L. H., Dahlerup, J. F., & Hvas, C. L. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819843002 · Cited by 30
“…transplantation (FMT) is an emerging therapeutic option for rCDI and is superior to both high-dose 10 and tapered 11 vancomycin as well as autologous FMT. 19 Resolution rates of 70–90% following FMT for rCDI have been consistently reported in both observational studies 20–24 and randomized trials.”
BackgroundInfluentialZhang, Y., Fleur, A. S., & Feng, H. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2052698 · Cited by 30
Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan
Wu, K.-S., Syue, L.-S., Cheng, A., Yen, T., Chen, H.-M., Chiu, Y.-H., Hsu, Y., Chiu, C.-H., Su, T.-Y., Tsai, W.-L., et al. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.02.002 · Cited by 30
Therapies on the horizon forClostridium difficileinfections
McFarland, L. V. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1161025 · Cited by 29
Tang, L., Feng, W., Cheng, J.-J., & Gong, Y.-N. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03599-7 · Cited by 29
Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options
Mizusawa, M., Doron, S., & Gorbach, S. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0289-2 · Cited by 29
Aby, E. S., Vaughn, B. P., Enns, E. A., & Rajasingham, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac207 · Cited by 28
Obanda, D. N., Keenan, M. J., Page, R. C., Raggio, A. M., Taylor, C. M., Marx, B. D., Stout, R. W., Guice, J. L., Luo, M., Welsh, D. A., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.746515 · Cited by 28
Biliński, J., Dziurzyński, M., Grzesiowski, P., Podsiadły, E., Stelmaszczyk‐Emmel, A., Dzieciątkowski, T., Lis, K., Tyszka, M., Ozierański, K., Dziewit, Ł., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.872735 · Cited by 28
“, 2015) and three randomized clinical trials (Youngster et al., 2014; Cammarota et al., 2015; Lee et al., 2016) directly compared fresh and frozen fecal preparations.”
BackgroundZhong, S., Zeng, J., Deng, Z., Jiang, L., Zhang, B., Yang, K., Wang, W., & Zhang, T. (2019) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-019-0708-9 · Cited by 28
Youngster, I., & Gerding, D. N. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.91 · Cited by 28
Self-citationBanking feces: a new frontier for public blood banks?
Baunwall, S. M. D., Hvas, C. L., Dahlerup, J. F., Mikkelsen, S., Ehlers, L. H., Hammeken, L. H., Licht, T. R., Bahl, M. I., & Erikstrup, C. (2019) · Transfusion · doi:10.1111/trf.15422 · Cited by 27
Clostridium difficile Infection
Shin, J. H., Chaves‐Olarte, E., & Warren, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.ei10-0007-2015 · Cited by 27
Carlucci, C., Jones, C. S., Oliphant, K., Yen, S., Daigneault, M. C., Carriero, C., Robinson, A. V., Petrof, E. O., Weese, J. S., & Allen‐Vercoe, E. (2019) · Scientific Reports · doi:10.1038/s41598-018-37547-x · Cited by 27
Kim, K. O., Schwartz, M. A., Lin, O. S. T., Chiorean, M. V., & Glück, M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00974-x · Cited by 27
Kumar, V., & Fischer, M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1689952 · Cited by 27
Scheeler, A. (2019) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110519897729 · Cited by 28
Zou, B., Liu, S., Dong, C., Shen, H., Lv, Y., He, J., Li, X., Ruan, M.-L., Huang, Z., & Shu, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05832-1 · Cited by 26
“Oral FMT capsules have demonstrated clinical efficacy for recurrent Clostridium difficile infection (CDI) [19, 20].”
Update on gut microbiota in gastrointestinal diseases
Nishida, A., Nishino, K., Ohno, M., Sakai, K., Owaki, Y., Noda, Y., & Imaeda, H. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i22.7653 · Cited by 25
Fecal Microbiota Transplantation for Fibromyalgia: A Case Report and Review of the Literature
Thurm, T., Ablin, J. N., Buskila, D., & Maharshak, N. (2017) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2017.74015 · Cited by 25
Comparative effectiveness of faecal microbiota transplant by route of administration
Gundacker, N. D., Tamhane, A. R., Walker, J. B., Morrow, C. D., & Rodriguez, J. M. (2017) · Journal of Hospital Infection · doi:10.1016/j.jhin.2017.05.004 · Cited by 25
An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection
Vedantam, G., Kochanowsky, J. A., Lindsey, J., Mallozzi, M., Roxas, J. L., Adamson, C. C., Anwar, F., Clark, A. E., Claus-Walker, R. A., Mansoor, A., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02080 · Cited by 25
“In randomized trials, FMT efficacy ranges from ∼50% to 90% based on delivery and number of infusions (van Nood et al., 2013; Youngster et al., 2014; Cammarota et al., 2015; Kelly et al., 2016; Lee et al., 2016), but this procedure is logistically challenging and could pose undefined risks to patients (Wang et al.”
BackgroundCausal role of the gut microbiome in certain human diseases: a narrative review
Prosty, C. J., Katergi, K., Papenburg, J., Lawandi, A., Lee, T. C., Shi, H., Burnham, P., Swem, L. R., Routy, B., Yansouni, C. P., et al. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100086 · Cited by 24
“25 In total, 19 RCTs of microbiome therapies for CDI met inclusion criteria 6 7 26–42 (figure 2).”
The diagnostic potential and barriers of microbiome based therapeutics
Acharjee, A., Singh, U., Choudhury, S. P., & Gkoutos, G. V. (2022) · Diagnosis · doi:10.1515/dx-2022-0052 · Cited by 24
Microbiota and Autism: A Review on Oral and Gut Microbiome Analysis Through 16S rRNA Sequencing
Anaclerio, F., Minelli, M., Antonucci, I., Gatta, V., & Stuppia, L. (2024) · Biomedicines · doi:10.3390/biomedicines12122686 · Cited by 24
“Advanced bioinformatics platforms, such as MicrobiomeAnalyst, QIIME 2, and emerging AI-driven systems like Deep Microbiome and MetaML, have shown potential in processing and visualizing multi-omics data.”
Greffe de microbiote fécal et infections: Mise au point, perspectives
Lagier, J., & Raoult, D. (2016) · médecine/sciences · doi:10.1051/medsci/20163211015 · Cited by 24
Tun, K. M., Hong, A. S., Batra, K., Naga, Y. S. E., & Ohning, G. (2022) · Cureus · doi:10.7759/cureus.25537 · Cited by 24
“The resolution was observed in 70% and 95% of 20 patients after the first and multiple treatments, respectively [28,29].”
BackgroundAdvances in fecal microbiota transplantation for the treatment of diabetes mellitus
Zhang, J., Wang, H., Liu, Y., Shi, M., Zhang, M., Zhang, H., & Chen, J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1370999 · Cited by 23
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection
Fehér, C., Soriano, À., & Mensa, J. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0140-z · Cited by 23
“With the demonstration that the efficacy of previously recollected frozen and freshly harvested microbiota have the same efficacy, intestinal microbiota transplantation has become a lot less cumbersome than before [210, 211].”
BackgroundThe Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly
Cheng, Y., & Fischer, M. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0143-1 · Cited by 23
“At least in the treatment of CDI, there appears to be no difference in efficacy between frozen and fresh stools [9, 10].”
BackgroundFecal microbiota transplantation in children: current concepts
Gurram, B., & Sue, P. K. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000787 · Cited by 23
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna, S. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13290 · Cited by 23
Faecal microbiota transplantation—the Austrian approach
Kump, P. K., Krause, R., Allerberger, F. J., & Högenauer, C. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12801 · Cited by 23
“In such cases, faecal samples should be stored at 80°C and gently reheated in a 37°C warm water bath over a period of 2 h [32,36,37].”
BackgroundMethodDiverticulitis after Fecal Microbiota Transplant for C. difficile Infection
Mandalia, A. B., Kraft, C. S., & Dhere, T. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.350 · Cited by 23
Ray, A., & Jones, C. R. (2016) · Future Microbiology · doi:10.2217/fmb.16.10 · Cited by 23
Reigadas, E., Olmedo, M., Valerio, M., Vázquez‐Cuesta, S., Alcalá, L., Marín, M., Muñóz, P., & Bouza, E. (2018) · Europe PMC (PubMed Central) · Cited by 22
van Lingen, E., Baunwall, S. M. D., Lieberknecht-Jouy, S. C., Benech, N., Ianiro, G., Sokol, H., Gasbarrini, A., Cammarota, G., Eriksen, M. K., Jong, A. E. V. D. M., et al. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231156285 · Cited by 21
Patel, P., Robinson, P. D., Fisher, B. T., Phillips, R., Morgan, J. E., Lehrnbecher, T., Kuczynski, S., Koenig, C., Haeusler, G. M., Esbenshade, A. J., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102604 · Cited by 21
Fecal microbiota transplantation for Clostridium difficile infection: back to the future
Borgia, G., Maraolo, A. E., Foggia, M., Buonomo, A. R., & Gentile, I. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1045872 · Cited by 21
“conducted a randomized, open-label, controlled pilot study to evaluate the effect of frozen FMT inocula from unrelated volunteer donors in RCDI patients, and found that this strategy was safe and effective [88].”
BackgroundVigvári, S., Sipos, D., Solt, J., Vincze, Á., Kocsis, B., Nemes, Z., Kappéter, Á., Feiszt, Z., Kovács, B., & Péterfi, Z. (2017) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.64.2017.042 · Cited by 21
Obanda, D. N., Husseneder, C., Raggio, A. M., Page, R. C., Marx, B. D., Stout, R. W., Guice, J. L., Coulon, D. B., & Keenan, M. J. (2020) · Nutrition · doi:10.1016/j.nut.2020.110893 · Cited by 21
Rules of the game for microbiota
Faust, K., & Raes, J. (2016) · Nature · doi:10.1038/534182a · Cited by 21
Elhusein, A. M., & Fadlalmola, H. A. (2022) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000652 · Cited by 20
Lin, T.-C., Hung, Y., Ko, W., & Ruan, J. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.08.009 · Cited by 20
Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem
Principi, N., Gnocchi, M., Gagliardi, M., Argentiero, A., Neglia, C., & Esposito, S. (2020) · Microorganisms · doi:10.3390/microorganisms8111640 · Cited by 20
“have shown that this vaccine was safe and immunogenic in adults aged 65–85 years [95].”
BackgroundThe Antimicrobial Stewardship Approach to Combating Clostridium Difficile
Wenzler, E., Mulugeta, S., & Danziger, L. H. (2015) · Antibiotics · doi:10.3390/antibiotics4020198 · Cited by 20
“A recently introduced alternative using frozen fecal suspensions from pooled donors administered via nasogastric tube or by capsule has shown similar success rates and greater feasibility [63,64].”
BackgroundCryopreservation of the human gut microbiota: Current state and perspectives
Smirnova, D. V., Заломова, Л. В., Zagaynova, A. V., Makarov, V. V., Mezhevikina, L. M., Fesenko, E. E., & Yudin, S. M. (2019) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2019.06.001 · Cited by 20
Mullish, B. H., Marchesi, J. R., Thursz, M. R., & Williams, H. R. T. (2014) · QJM · doi:10.1093/qjmed/hcu182 · Cited by 20
Fecal microbiota transplant for Clostridium difficile infection in older adults
Tauxe, W. M., Haydek, J. P., Rebolledo, P. A., Neish, E., Newman, K. L., Ward, A., Dhere, T., & Kraft, C. S. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15622600 · Cited by 19
Hota, S. S., Surangiwala, S., Paterson, A. S., Coburn, B. A., & Poutanen, S. M. (2018) · CMAJ Open · doi:10.9778/cmajo.20170109 · Cited by 19
Svensson, C. K., Cold, F., Ribberholt, I., Zangenberg, M., Mirsepasi‐Lauridsen, H. C., Petersen, A. M., & Helms, M. (2022) · Cells · doi:10.3390/cells11203272 · Cited by 18
Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom
Porter, R. J., & Fogg, C. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.01.020 · Cited by 17
“The use of frozen faecal solution [17] will improve accessibility to prescreened stool and appears to have a similar efficacy [18].”
BackgroundChallenges of Screening Prospective Stool Donors for Fecal Microbiota Transplantation
Dubois, N. E., Read, C. Y., OʼBrien, K., & Ling, K. (2020) · Biological Research For Nursing · doi:10.1177/1099800420941185 · Cited by 17
“Despite reported high efficacy rates in treating recurrent CDI (van Nood et al., 2013; Youngster et al., 2014), the logistics for finding suitable donors continues to be a complicated process reporting deferral rates between 90% and 96% (Dubois et al., 2015; Paramsothy et al., 2015).”
BackgroundZeng, C., Liu, X., Xiong, D., Zou, K., & Bai, T. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07356-w · Cited by 17
“The standards of grading were as described previously [30, 31].”
MethodTariq, R., Pardi, D. S., & Khanna, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231174293 · Cited by 17
Management of Primary and Recurrent Clostridium difficile Infection: An Update
Chai, J., & Lee, C. (2018) · Antibiotics · doi:10.3390/antibiotics7030054 · Cited by 17
“While many studies use multiple administrations of FMT in determining efficacy rates, single administrations of FMT may have lower CDI resolution rates with reported values of 62%, 65%, and 70% in 3 different RCTs [29,33,34].”
BackgroundInfluentialPractical implementation of faecal transplantation
Kapel, N., Thomas, M., Corcos, O., Mayeur, C., Barbot, L., Bouhnik, Y., & Joly, F. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12796 · Cited by 16
“However, no storage of >156 days has yet been described [15].”
BackgroundInfluentialHota, S. S., & Poutanen, S. M. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy045 · Cited by 16
“In a pilot randomized trial comparing FMT by nasogastric (NG) tube with colonoscopy administration, only 60% of the patients in the NG tube arm achieved RCDI resolution after a single administration, while a second administration raised success to 80% [8].”
BackgroundIakupova, A. A., Abdulkhakov, S. R., Safin, A., Alieva, I., Oslopova, J. V., & Abdulkhakov, R. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.02.200615 · Cited by 16
Borody, T. J., Connelly, N. J., & Mitchell, S. W. (2015) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3166 · Cited by 16
Dowle, C. (2016) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzw007 · Cited by 16
“Youngster et al. (2014) inoculated patients with faecal material that had been previously frozen.”
BackgroundMethodResultInfluentialRao, K. K., Young, V. B., & Malani, P. (2017) · JAMA · doi:10.1001/jama.2017.17969 · Cited by 16
Jaramillo, A. P., Awosusi, B. L., Ayyub, J., Dabhi, K. N., Gohil, N. V., Tanveer, N., Hussein, S., Pingili, S., & Makkena, V. K. (2023) · Cureus · doi:10.7759/cureus.42120 · Cited by 15
“showed that the participants' symptoms were alleviated in 70% after one FMT and in 90% of patients after several FMTs [15].”
BackgroundInfluentialRakotonirina, A., Galpérine, T., & Allémann, É. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2095901 · Cited by 16
“efficacy is comparable if the donor is from the patient’s family or inner social circle or is unrelated person [32].”
BackgroundLin, C., Wan, J., Lü, Y., Zhang, H., Chen, X., Su, Y., & Zhu, W. (2019) · AMB Express · doi:10.1186/s13568-019-0787-4 · Cited by 15
Trasplante de microbiota fecal: primer caso reportado en Chile y revisión de la literatura
Espinoza, R., Quera, R., Meyer, L., & Rivera, D. (2014) · Revista chilena de infectología · doi:10.4067/s0716-10182014000400016 · Cited by 15
Microbiology and Ecology Are Vitally Important to Premedical Curricula
Smith, V. H., Rubinstein, R., Park, S., Kelly, L., & Klepac‐Ceraj, V. (2015) · Evolution Medicine and Public Health · doi:10.1093/emph/eov014 · Cited by 15
“difficile in patients with chronic recurrent disease and provide strong empirical support for fecal microbiota transplants as a novel therapy [102, 103].”
BackgroundCRISPRs for Strain Tracking and Their Application to Microbiota Transplantation Data Analysis
Lam, T. J., & Ye, Y. (2019) · The CRISPR Journal · doi:10.1089/crispr.2018.0046 · Cited by 15
Fecal Microbiota Therapy With a Focus on Clostridium difficile Infection
Brandt, L. J. (2017) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000511 · Cited by 14
Messias, B. A., FRANCHI, B. F., Pontes, P. H., BARBOSA, D. Á. D. A. M., & VIANA, C. A. S. (2018) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20181609 · Cited by 14
Faecal microbiota transplantation
Nieuwdorp, M. (2014) · British journal of surgery · doi:10.1002/bjs.9549 · Cited by 14
Faecal Microbiota Transplantation as Emerging Treatment in European Countries
Maida, M. F., Mcilroy, J. R., Ianiro, G., & Cammarota, G. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_11 · Cited by 13
Lee, P., Chang, T.-E., Wang, Y., Lee, K., Lin, Y.-T., Chiou, J.-J., Huang, C.-W., Yang, U., Li, F.-Y., Huang, H., et al. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.11.001 · Cited by 13
Clostridioides (Clostridium) Difficile Infection: Current and Alternative Therapeutic Strategies
Gil, F., Calderón, I. L., Fuentes, J. A., & Paredes‐Sabja, D. (2018) · Future Microbiology · doi:10.2217/fmb-2017-0203 · Cited by 13
Management of adult Clostridium difficile digestive contaminations: a literature review
Mathias, F., Curti, C., Montana, M., Bornet, C., & Vanelle, P. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3419-z · Cited by 13
Hernández-Rocha, C., Pidal, P., Ajenjo, M. C., Quera, R., Quintanilla, M., Lubascher, J., Jemenao, M. I., Patricio Ibáñez, L., Álvarez-Lobos, M., Alexis Diomedi, P., et al. (2016) · Revista chilena de infectología · doi:10.4067/s0716-10182016000100020 · Cited by 13
Majors, D., & Ellis, P. (2015) · Hospital Pharmacy · doi:10.1310/hpj5011-1003 · Cited by 13
Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection
Johnson, S., & Gerding, D. N. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw735 · Cited by 13
Shetty, S. A. (2019) · doi:10.18174/468013 · Cited by 13
Minotti, C., Barbieri, E., Giaquinto, C., & Donà, D. (2021) · Pathogens · doi:10.3390/pathogens10101343 · Cited by 12
Li, K., Hu, Z., Ou, J., & Xia, K. (2019) · Global Clinical and Translational Research · doi:10.36316/gcatr.01.0006 · Cited by 12
From Expert Protocols to Standardized Management of Infectious Diseases
Lagier, J., Aubry, C., Delord, M., Michelet, P., Tissot‐Dupont, H., Million, M., Brouqui, P., Raoult, D., & Parola, P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix403 · Cited by 12
“Although simplified by using the nasogastric route and freezing the microbiota [38], fecal microbiota transplantation remains”
MethodMehmood, K., Moin, A., Hussain, T., Rizvi, S. M. D., Gowda, D., Shakil, S., & Kamal, M. (2021) · Folia Microbiologica · doi:10.1007/s12223-021-00926-5 · Cited by 12
Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.
(2016) · Europe PMC (PubMed Central) · Cited by 12
Biotic resistance predictably shifts microbial invasion regimes
Ye, X., Shalev, O., & Ratzke, C. (2025) · Nature Communications · doi:10.1038/s41467-025-59285-1 · Cited by 11
Host origin of microbiota drives functional recovery and Clostridioides difficile clearance in mice
Millard, S., Vendrov, K. C., Young, V. B., & Seekatz, A. M. (2025) · mBio · doi:10.1128/mbio.01108-25 · Cited by 11
“Specifically, many genera frequently associated with resistance to or recovery from C. difficile in mouse and human studies (30, 34, 64) were increased following both hFMT and mFMT, including Bacteroides and unclassified Lachnospiraceae species (Fig.”
Gong, J., Liu, Y., & Huang, L. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1637673 · Cited by 11
Goldenberg, S. D. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.12.004 · Cited by 11
Fecal microbiota transplantation donation: the gift that keeps on giving
Turse, E. P., Dailey, F. E., Ghouri, Y. A., & Tahan, V. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.009 · Cited by 11
Ince, M. N., Blazar, B. R., Edmond, M. B., Tricot, G. J. K., & Wannemuehler, M. J. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000599 · Cited by 11
“Two of the 3 trials compared FMT with oral vancomycin,(73,75) whereas the third compared FMT delivered by the nasogastric route with delivery through colonoscopy.(74) Another emerging therapeutic application of FMT is for multidrugresistant pathogen decolonization of the gastrointestinal tract.”
ResultQuera, R., Patricio Ibáñez, L., Simian, D., Rivera, D., Guillermo Acuña, L., & Espinoza, R. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018000800823 · Cited by 11
Hong, A. S., Yu, W. Y., Hong, J. M., Cross, C. L., Azab, M., Ohning, G., & Jayaraj, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14958 · Cited by 11
STRUCTURING A FECAL MICROBIOTA TRANSPLANTATION CENTER IN A UNIVERSITY HOSPITAL IN BRAZIL
Terra, D., Vilela, E. G., Silva, R. O. S., LEÃO, L. A., Karine Sampaio, L. I. M. A., PASSOS, R. I. F. Â., Diniz, A. N., & Coelho, L. G. V. (2020) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202000000-79 · Cited by 11
“In most studies, manipulation occurs under aerobic conditions without impairing the effectiveness of the treatment(46,96-102).”
BackgroundInfluentialA Review of Management of Clostridium difficile Infection: Primary and Recurrence
Vincent, Y. M., Manji, A., Gregory-Miller, K., & Lee, C. (2015) · Antibiotics · doi:10.3390/antibiotics4040411 · Cited by 11
“No recurrence or relapse was observed in clinically cured patients in either arm in the eight week follow up period [61].”
BackgroundFecal microbiota transplantation for recurrent Clostridioides difficile infection
Haber, S. L., Raney, C. R. K., Larson, T., & Lau, J. P. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz078 · Cited by 11
Hauser, G., Horvat, I. B., Rajilić-Stojanović, M. D., Zrnić, I. K., Kukla, M., Aljinović-Vučić, V., & Mikolašević, I. (2025) · Biomedicines · doi:10.3390/biomedicines13040779 · Cited by 10
Current and future targets for faecal microbiota transplantation
Mcilroy, J. R., Segal, J. P., Mullish, B. H., Quraishi, M. N., Gasbarrini, A., Cammarota, G., & Ianiro, G. (2018) · Human Microbiome Journal · doi:10.1016/j.humic.2018.08.004 · Cited by 10
Debré, P., & Gall, J. L. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31175-6 · Cited by 11
Jugan, M. C., KuKanich, K. S., & Freilich, L. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1050538 · Cited by 10
Onifade, I. A., Sunbare-Funto, O. J., Mbah, C. G., Ajibade, O. A., Oyawoye, O. M., Aborode, A. T., Ogunleye, S. C., Jamiu, A. T., Bolarinwa, B., Abanikannda, M. F., et al. (2024) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2024.02.001 · Cited by 10
Metadata
- Authors
- Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Youngster, Ilan
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 58
- Issue
- 11
- Pages
- 1515-1522
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4017893
- OpenAlex
- W2146116383
- Cited by
- 467
- References
- 32
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 31 · 2023: 22 · 2022: 24 · 2021: 35 · 2020: 37 · 2019: 51 · 2018: 47 · 2017: 57 · 2016: 53 · 2015: 61 · 2014: 27
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000170)
- National Institute of Allergy and Infectious Diseases (HHSN272200900018C)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, unrelated donor, nasogastric tube administration, diarrhea resolution, health-related quality of life, antibiotic-refractory infection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy, Child, Clostridium Infections, Colonoscopy, Diarrhea, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.